BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin N, Liu Q, Wang M, Wang Q, Zeng K. Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity. PeerJ 2018;6:e5388. [PMID: 30083474 DOI: 10.7717/peerj.5388] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Kong X, Wang J, Cao Y, Zhang H, Lu X, Wang Y, Bo C, Wang T, Li S, Tian K, Liu Z, Wang L. The long noncoding RNA MALAT-1 functions as a competing endogenous RNA to regulate MSL2 expression by sponging miR-338-3p in myasthenia gravis. J Cell Biochem 2019;120:5542-50. [PMID: 30362606 DOI: 10.1002/jcb.27838] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
2 Xu M, Liu Q, Li S, Zhang W, Huang X, Han K, Li C, Zeng K. Increased expression of miR-338-3p impairs Treg-mediated immunosuppression in pemphigus vulgaris by targeting RUNX1. Exp Dermatol 2020. [PMID: 32386260 DOI: 10.1111/exd.14111] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Papara C, Zillikens D, Sadik CD, Baican A. MicroRNAs in pemphigus and pemphigoid diseases. Autoimmun Rev 2021;20:102852. [PMID: 33971341 DOI: 10.1016/j.autrev.2021.102852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tavakolpour S, Mahmoudi H, Karami F, Elikaei Behjati S, Balighi K, Abbasi M, Salehi Farid A, Masoudi J, Balali M, Daneshpazhooh M, Modarressi MH. Investigating expression pattern of eight immune‐related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: Potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy. Dermatologic Therapy 2020;33. [DOI: 10.1111/dth.14380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Nili A, Salehi Farid A, Asgari M, Tavakolpour S, Mahmoudi H, Daneshpazhooh M. Current status and prospects for the diagnosis of pemphigus vulgaris. Expert Rev Clin Immunol 2021;17:819-34. [PMID: 34162306 DOI: 10.1080/1744666X.2021.1945925] [Reference Citation Analysis]
6 Qiu L, Zhang L, Qi R, Gao X, Chen H, Xiao T. miR-1291 Functions as a Potential Serum Biomarker for Bullous Pemphigoid. Dis Markers 2020;2020:9505312. [PMID: 32399091 DOI: 10.1155/2020/9505312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Reolid A, Muñoz-Aceituno E, Abad-Santos F, Ovejero-Benito MC, Daudén E. Epigenetics in Non-tumor Immune-Mediated Skin Diseases. Mol Diagn Ther 2021;25:137-61. [PMID: 33646564 DOI: 10.1007/s40291-020-00507-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Delavarian Z, Layegh P, Pakfetrat A, Zarghi N, Khorashadizadeh M, Ghazi A. Evaluation of desmoglein 1 and 3 autoantibodies in pemphigus vulgaris: correlation with disease severity. J Clin Exp Dent 2020;12:e440-5. [PMID: 32509225 DOI: 10.4317/jced.56289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]